Open Nav

Genprex, Inc.

  • Julien Pham, Genprex, Inc.

Gain visibility with investors

  • Date:Thursday, October 18
  • Time:9:30 AM - 9:45 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:Genprex™ is a clinical stage gene therapy company developing a new approach to treating cancer, based on our novel proprietary technology platform, including our initial product candidate - Oncoprex™ immunogene therapy - or, Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. We are currently conducting the second phase of a Phase I/II clinical trial
  • Company Website:
  • Company HQ City:Austin, TX/ Cambridge, MA
  • Company HQ Country:United States
  • Company HQ State:Texas                            
  • Ticker:GNPX
  • Exchange:Nasdaq
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :Oncoprex
  • Development Phase of Primary Product:Phase II
Julien Pham
Genprex, Inc.